

FORMUTECH 2026

mRNA Process Development
& Manufacturing | LNP Formulations



14 - 15
OCTOBER



HOTEL EUROSTARS
UNIVERSAL - LISBON, PT



DIAMOND SPONSORS

SARTORIUS

UNCHAINED
LABS

GOLD SPONSORS

 **LEON**
ENABLING NANO NOW

SILVER SPONSORS

 4basebio®


eXmoor

 **cytiva**

EVENT PARTNERS

 **SPARTA**
BIODISCOVERY

ANEMCOYTE
Manufacturing Biotech Innovation

IRUBIS

MEDIA PARTNERS

 **BioPharma**
Asia

 **Bio-Equip**
www.bio-equip.cn

Bio
Pharma
Trend

Gene Therapy Net
www.genetherapynet.com
• Breaking News
• Conferences
• Clinical Trials
• Viral Vectors
• Legislation
• Societies
The support for all your information about gene therapy

KC | World With Science
www.kindcongress.com

 **LAB**
WORLD

 **Medhealth Outlook**

PHARMA
network
magazine



The FormuTech Summit returns in 2026, bringing together global leaders in mRNA therapeutics, LNP technologies, process development, manufacturing, analytical science, and regulatory strategy.

Hosted in Lisbon, the summit will examine the critical challenges involved in advancing RNA medicines from molecular and formulation design through characterization, manufacturing, and therapeutic translation. Across two days, the program will explore advances in RNA engineering and IVT, LNP design and formulation, analytical characterization, process monitoring, scalable manufacturing, product readiness, and regulatory expectations.

Through scientific presentations, industry case studies, and interactive panel discussions, attendees will gain practical perspectives on improving product quality, process robustness, manufacturability, scalability, and CMC readiness, while examining the technologies and strategies shaping the next generation of RNA therapeutics.



SCREEN SMART. WASTE LESS. SCALE WITH CONFIDENCE.

Discovery-scale LNP formulation screening built for the path to GMP.

NANO screen

- Minimum material loss at screening scale
- Smart design that makes every run feel safe
- Automated cleaning built-in
- FR-JET® Technology with reusable or extended single-use mixer.
- Beyond LNPs - one platform for your entire formulation pipeline
- Scale-up continuity



www.leon-nanodrugs.com

leon-nanodrugs GmbH, Am Klopferspitz 19, D-82152 Planegg, Germany







Learn The Key Practical Points

Next-Generation LNP Engineering & Formulation

Explore advances in lipid design, formulation optimization, and LNP development strategies aimed at improving potency, robustness, and therapeutic performance of mRNA-LNP systems.

Advanced Characterization of RNA & LNPs

Discover analytical approaches for evaluating RNA and LNP quality, including particle size, structural heterogeneity, purity, and critical quality attributes using technologies such as HPLC, mass spectrometry, and advanced particle characterization.

AI-Driven RNA Design & Predictive Development

Learn how computational tools and algorithm-driven pipelines are integrating in silico, in vitro, and in vivo data to accelerate RNA design, formulation development, and translational decision-making.

Real-Time Process Monitoring & PAT Integration

Understand how in-line analytics and Process Analytical Technology (PAT) can strengthen process control, improve reproducibility, and support optimization of IVT processes and reduction of critical impurities such as dsRNA.

Stability & Product Readiness of RNA Therapeutics

Examine strategies for improving the stability and product readiness of RNA-LNP medicines, including freeze-drying, formulation robustness, storage, and considerations for downstream therapeutic use.

RNA Engineering, IVT & Emerging RNA Formats

Explore advances in RNA engineering, IVT optimization, enzymatic capping, emerging mRNA formats, and synthetic biology approaches enabling more efficient and versatile RNA medicines.



Scalable Manufacturing & Industrialization Strategies

Explore manufacturing technologies, process design, automation, and scalable production strategies supporting the transition of RNA therapeutics from development to reproducible GMP manufacturing.

Personalized & Programmable RNA Medicines

Explore advances in individualized and programmable RNA therapeutics, including personalized cancer immunotherapies and emerging approaches designed to translate RNA technologies into increasingly tailored therapeutic applications.

Regulatory Expectations & CMC Readiness

Understand evolving regulatory perspectives on RNA medicines, including analytical expectations, manufacturing controls, quality frameworks, personalized therapies, and CMC considerations for complex RNA products.

Therapeutic Translation & Future RNA Platforms

Explore how advances in programmable RNA medicines, personalized mRNA therapeutics, LNP technologies, manufacturing, and emerging RNA platforms are translating scientific innovation toward clinical and commercial applications.



EPM Group Executive Summary

WHO You Will Meet



80+
Attendees




20+
Speakers

RATIO


Bio/pharmaceutical manufacturing **65:35** Vendor/Solution Providers

Company Size of Attendees




- 1000+ employees
- 300-999 employees
- 50-299 employees
- less than 49 employees

Job Title of Attendees



- C-level
- SVP/VP
- Snr Director/Director
- Snr Manager/Manager

Attendee Company Annual Turnover



- 1 Billion
- \$500-999 Million
- \$50-499 Million
- <50 Million

HOW You Will Benefit



x1000+

Relive the conference full Access to documentation, footages and videos.



x10+

Hours of Networking forge new professional contacts.



x20+

Technical Presentations & Case Studies

Companies Attending Our Events



94%

RATED EVENT



FEEDBACK

Quality of the speakers
Sharing of the best practices
Spectrum of industries
Intimate atmosphere

98%

WOULD RECOMMEND
THE EVENT TO
COLLEAGUES

Meet The Speakers



**Eike F.
Joest**



Head of Downstream Science
& Applications at Merck
KGaA



**Ben
Knappett**



Senior Product Manager
at Unchained Labs



**Katie
Randall**



Senior Associate Scientist
at Sanofi



**Barbara
Beneduci**



mRNA Modality Leader -
EMEA at Merck KGaA



**Aishu
Parthasarathy**



Associate at Sofinnova
Partners



**Ka-Wai
Wan**



Leading Senior
Pharmaceutical Assessor
at MHRA



**Christopher
van der Walle**




Head of Formulation Science
at MHRA



**Xiaojing
Gao**



Assistant Professor at
Stanford University



**Felix
Sieber-Schäfer**



Researcher
at LMU Munich



**Steve
Pascolo**



Principal Investigator at
University Hospital of Zurich



**Quentin
Hualmé**



Senior Research Scientist
at Sartorius



**Rein
Verbeke**



Senior postdoc at Ghent
University (NanoMedicine
Centre)



**Maciej
Drozd**

Co-founder and CBO
at MiMo Biotech



**Mark
Dickman** 

Professor of Bioanalytical
Science and Engineering at
University of Sheffield



**Deborah
Entiriwaa** 

DNA Operations Team
Leader at 4basebio



**Michel
Bajot** 

Board Director at RNAlead
and Chairman at White Fund



**Andreas
Kuhn** 

Senior Vice President
RNA Biochemistry & CMC
Development at BioNTech



**Marco
Pupo** 

Innovation and Development
Coordinator at ANEMOCYTE
Srl




**Blerina
Shkodra** 

Chief Scientific Officer
at leon-nanodrugs GmbH



**Harvey
Branton** 

Senior Translation Consultant
at eXmoor Pharma




**Charles
Chesnelong** 

Field Application Scientist
at Cytiva



**Andrea
Cusack** 

CEO
at Nebu~flow



**Sabine
Maamari** 

Chief Operating Officer
at Avocet Bio

Scientific Agenda

DAY 0 TUESDAY, OCTOBER 13TH

18:00 - 19:30 | Pre-Conference Cocktail
Reception at Hotel Eurostars
Universal Lisbon

DAY 1 WEDNESDAY, OCTOBER 14TH

8:00 - 8:30 | FormuTech Registration
& Welcome Coffee

Morning Chairperson:
Eike F. Joest, Merck KGaA

8:30 - 9:00 | Launch of the European
White Paper on mRNA & LNP
Manufacturing

Session 1: Advanced LNP Engineering & Formulation Optimization

9:00 - 9:30 | An ionizable LNP platform for
scalable in vivo CAR T cell and
HSC engineering
Charles Chesnelong Field
Application Scientist at Cytiva

9:30 - 10:00 | Topic to be announced by
Unchained Labs
**Ben Knappett, Senior Product
Manager at Unchained Labs**

10:00 - 10:30 | Speed Networking

10:30 - 11:00 | Morning Coffee Break

11:00 - 11:30 | Enabling tomorrow's RNA
therapies – from lab to patients
at scale
**Blerina Shkodra, Chief
Scientific Officer at leon-
nanodrugs GmbH**

11:30 - 12:00 | An Innovative Cationic Lipid
Library for Efficient and Tunable
mRNA-LNPs
**Quentin Huauilmé, Senior
Research Scientist at Sartorius**

12:00 - 12:30 | Design, Formulation
Optimization, and Process
Improvements for mRNA LNPs
**Katie Randall, Senior Associate
Scientist at Sanofi**

12:30 - 13:00 | LNP Formulation Design,
Characterization & Robustness
**Andrea Cusack, CEO
at Nebu-Flow**

13:00 - 14:00 | Lunch Break

Afternoon Chairperson:
Andreas Kuhn, BioNTech

Session 2: Advanced RNA & LNP Development: Characterization, Translation & Manufacturability

14:00 - 14:30 | Analytical Characterization
of Size and Structural
Heterogeneity in mRNA Lipid
Nanoparticles
**Rein Verbeke, Senior
postdoc at Ghent University
(NanoMedicine Centre)**

14:30 - 15:00 | New Methods for the
Characterisation of mRNA
Medicines Using HPLC and
Mass Spectrometry
**Mark Dickman, Professor of
Bioanalytical Science and
Engineering at University of
Sheffield**

15:00 - 15:30	Programmable RNA Medicines: From Molecular Design to Therapeutic Translation Sabine Maamari, Chief Operating Officer at Avocet Bio
15:30 - 16:00	Designing for Future Scale: How Early Manufacturing Choices Shape RNA-LNP Cost and Flexibility Harvey Branton, Senior Translation Consultant at eXmoor Pharma
16:00 - 16:30	Afternoon Coffee Break & Sartorius Sponsor Presentation
16:30 - 17:30	Panel Discussion: Scaling RNA Therapeutics Beyond Proof- of-Concept: Can the Industry Deliver Reproducible, Cost- Efficient & Globally Scalable RNA Medicines? • Scale-Out vs. Scale-Up Manufacturing Models • Reproducibility & Analytical Harmonization in RNA-LNP Systems • AI & Automation in Process Optimization • Manufacturing Challenges Beyond Vaccines • GMP Readiness as a Competitive Advantage Panelists: • Andreas Kuhn – BioNTech • Barbara Beneduci – Merck KGaA • Ka-Wai Wan – MHRA • Harvey Branton – eXmoor Pharma • Felix Sieber-Schäfer – LMU Munich Moderated by Mark Dickman, University of Sheffield
20:00 - 22:00	FormuTech Conference Dinner at Hotel Eurostars Universal Lisbon

DAY 2	THURSDAY, OCTOBER 15TH
8:30 - 8:45	Day 2 FormuTech Registration & Coffee
Morning Chairperson: Sabine Maamari, Avocet Bio	
Session 3: RNA Engineering, IVT Innovation & Next-Generation mRNA Design	
8:45 - 9:15	ALINA: Aligning in silico, in vitro and in vivo data for a scalable RNA formulation algorithm- pipeline Felix Sieber-Schäfer Researcher at LMU Munich
9:15 - 9:45	RNA-Compatible Synthetic Biology for Human Health Xiaojing Gao, Assistant Professor at Stanford University
9:45 - 10:30	dsRNA Reduction Platform and Raman PAT: A Synergistic Approach to High-Yield IVT mRNA Manufacturing Barbara Beneduci, mRNA Modality Leader; Eike F. Joest, Head of Downstream Science & Applications at Merck KGaA
10:30 - 11:00	Morning Coffee Break & Unchained Labs Sponsor Presentation
Session 4: mRNA Manufacturing Technologies & Regulatory Readiness	
11:00 - 11:30	Regulatory Status of Personalised mRNA-based Cancer Immunotherapies – MHRA Perspective Ka-Wai Wan, Leading Senior Pharmaceutical Assessor at MHRA

11:30 - 12:00	Synthetic DNA: The new standard in scalable GMP-grade manufacture for mRNA therapeutics Deborah Entiriwaa, DNA Operations Team Leader at 4basebio
12:00 - 12:30	Streamlining mRNA Success: The AMCAP™ One-Pot Enzymatic Capping Revolution Marco Pupo, Innovation and Development Coordinator at Anemocyte
12:30 - 13:00	Formats of mRNA Enabling Optimised mRNA Vaccines Steve Pascolo, Principal Investigator at University Hospital of Zurich

13:00 - 14:00	Lunch Break
----------------------	-------------

Afternoon Chairperson:
Barbara Beneduci, Merck KGaA

Session 5: Manufacturing & Product Development of Advanced RNA Therapeutics

14:00 - 14:30	Manufacturing of individualized mRNA-based cancer immunotherapies Andreas Kuhn, Senior Vice President RNA Biochemistry & CMC Development at BioNTech
14:30 - 15:00	Freeze-Drying of RNA-LNPs: Challenges and Solutions Christopher van der Walle, Head of Formulation Science at Medicines and Healthcare products Regulatory Agency (MHRA)
15:00 - 16:00	Panel Discussion: Capital Allocation in mRNA & RNA Platforms: What Gets Funded, Scaled, or Repositioned? • De-Risking RNA Platforms Beyond the Vaccine Era • Manufacturability as a Strategic Investment Filter • AI-Enabled RNA Development & Digital Bioprocessing


- Future Investment Trends in RNA Delivery Systems
- Commercial Viability vs. Scientific Innovation

Panelists:

- Michel Baijot — RNAlead / White Fund
- Aishu Parthasarathy — Sofinnova Partners
- Maciej Drozd — MiMo Biotech
- Eike F. Joest — Merck KGaA
- Blerina Shkodra — LEON-nanodrugs

Moderated by: Michel Baijot — RNAlead / White Fund

16:00	End of FormuTech Summit 2026
--------------	------------------------------



The Perfect Fit.

Comprehensive pDNA and mRNA Solutions Made For You

Nucleic acid processes vary widely in vector design, expression systems, purification constraints, and regulatory expectations. Sartorius provides comprehensive solutions designed to provide maximum flexibility throughout your pDNA and mRNA development journey—from discovery and pre-clinical stages to commercial manufacturing.


 To learn more, visit <https://sar.to/theperfectfit>



Simplifying Progress

SARTORIUS

Speakers Biographies



Eike F. Joest

Head of Downstream Science & Applications at Merck KGaA

Eike is Principal Scientist for innovations and technologies in mRNA service offering. He was responsible for development of the upscaled mRNA manufacturing process and implementation of AmpTec™ technologies in R&D. Before joining Merck Life Science KGaA in Darmstadt, Germany, he demonstrated broad technical

expertise in synthetic biology and molecular biology by publishing in several peer-reviewed journals. Eike holds a M.Sc. with distinction in Biochemistry from Wuerzburg University and a summa cum laude Ph.D. in cellular Biochemistry from Frankfurt University.



Ben Knappett

Senior Product Manager at Unchained Labs

Ben Knappett is Product Manager for the Sunny Suite, Unchained Labs' automated microfluidic nanoparticle synthesis instruments, used primarily for LNP encapsulation in drug delivery, vaccines, and gene therapy applications. Ben received his MChem degree from Durham University, and completed a PhD in nanoparticle

synthesis and characterization at the University of Cambridge. Ben previously worked for Particle Works as Head of Science and Applications, playing a key role in the development and commercialization of the instruments that now make up the Sunny Suite.



Katie Randall

Senior Associate Scientist at Sanofi

Katie has worked in the Biotech industry for just over three years and has experience in Analytical Development, Process Development, and Delivery & Formulations across a variety of platforms. At Sanofi, she works on the Delivery

& Formulations team, screening lipid compositions, experimenting with novel processes, and working cross-functionally to formulate a wide range of LNPs.



Barbara Beneduci

mRNA Modality Leader - EMEA at Merck KGaA

With over 15 years of experience in the life sciences industry, Barbara Beneduci has developed deep expertise in advancing innovative solutions and fostering strategic partnerships in the biopharma industry. After earning a master's degree in biotechnology, she began her career as an R&D scientist before transitioning into a field role as a sales manager for biopharma materials, supporting pharmaceutical customers in process development and optimization. Currently, as the mRNA Modality Leader

for EMEA at Merck KGaA, she plays a key role in driving the growth and development of mRNA technologies. She interacts with pDNA/mRNA customers and key opinion leaders, collaborating closely with R&D and marketing teams to build Merck's innovation pipeline. Through her extensive exposure to pharma manufacturers, she is dedicated to leveraging her knowledge to enhance business strategies and facilitate collaborations that propel scientific advancements.



Aishu Parthasarathy

Associate at Sofinnova Partners

Aishu Parthasarathy is an Associate at Sofinnova Partners' Digital Medicine fund, where she focuses on early-stage healthcare and biotech companies at the intersection of AI and life sciences. Her interest in AI was shaped by her academic work in neuroscience, where she explored how cognition is encoded and represented in the brain, an experience that continues to inform her perspective on

the convergence of computational methods and biology. She previously worked at BioGeneration Ventures, contributing to early-stage investments across the European biotech ecosystem. Prior to venture capital, she completed a PhD in Systems and Computational Neuroscience, with a research focus on understanding cognition.



Ka-Wai Wan

Leading Senior Pharmaceutical Assessor at MHRA (Medicines and Healthcare products Regulatory Agency)

Dr Ka-Wai Wan is a pharmacist by training and graduated from The School of Pharmacy (University of London). She was trained as a hospital pharmacist before completing her PhD in nanomedicine at the Welsh School of Pharmacy (Cardiff, UK). Ka-Wai worked as an academic for over a decade and she was a Principal Lecturer in Pharmaceutics and Course Leader for the MSc Industrial Pharmaceutics from the School of Pharmacy and Biomedical Sciences

at the University of Central Lancashire (UCLan, Preston) before moving to work at the Medicines and Healthcare products Regulatory Agency (MHRA) in 2016. She is now a Senior Pharmaceutical Assessor at the MHRA, leading on the assessment of nano-based medicinal products, and providing scientific advice on innovative medicines, particularly on nanomaterials used for both small and macromolecules delivery.



Christopher van der Walle

Head of Formulation Science at Medicines and Healthcare products Regulatory Agency (MHRA)

After 14 years in academia researching dosage form design, Chris van der Walle moved to the biopharmaceutical industry, first developing formulations for monoclonal antibodies in MedImmune and then mRNA-lipid nanoparticles in AstraZeneca. He led the formulation team in GlaxoSmithKline developing CAR-T

cell therapies, and the Cell & Gene Therapy Catapult's Edinburgh facility, working on induced pluripotent stem cell stems. He is currently Head of Formulation Science at the MHRA, producing pilot batches of biological reference materials.




Xiaojing Gao

Assistant Professor at Stanford University

Dr. Xiaojing Gao received a B.S. in Biology from Peking University and a Ph.D. in Biology from Stanford University. He received his postdoctoral training from Biology and Biological Engineering at Caltech. His recent recognitions

include BioInnovation Institute & Science Prize for Innovation and NIH's New Innovator Award. His lab works on biomolecular controllers that can improve the precision of mRNA-delivered therapeutic payloads



Felix Sieber-Schäfer
Researcher at LMU Munich

Felix Sieber-Schäfer is a researcher working at the interface of machine learning, pharmaceutical formulation, and drug delivery. His work focuses on data-driven approaches to accelerate the development of complex formulation systems, particularly lipid nanoparticles for RNA delivery. A key focus of his research is developing active learning

approaches that can learn from the small, heterogeneous, and noisy datasets commonly encountered in pharmaceutical development. His broader goal is to integrate computational modelling and experimentation into iterative workflows that enable faster, more systematic, and more transferable formulation development.



Steve Pascolo
Principal Investigator at University Hospital of Zurich

Trained as an immunologist at the Pasteur Institute (Paris, France), Steve Pascolo used mouse models to test and develop mRNA-based vaccines (direct injection of mRNA) during his post-doc in Tuebingen, Germany from 1998 till 2000. In 2000, he co-founded CureVac with Dr. Hoerr and Dr. von der Mulbe. Steve Pascolo was Chief Scientific Officer (CSO) of the company from 2000 till 2006, developing the technology, implementing the worldwide first pharmaceutical (GMP) production of synthetic mRNA and starting in 2003 the worldwide first

clinical studies where humans (including first himself) got injections of in vitro transcribed mRNA. In 2006, he joined the oncology department of the University Hospital of Zurich, Switzerland and continued the development of immunotherapies based on RNA. In 2008, he founded Miescher Pharma to support this work. In 2013, he joined the dermatology department of the University Hospital of Zurich, Switzerland. In 2017, Steve Pascolo implemented in the University of Zurich an academic mRNA platform.



Quentin Huault
Senior Research Scientist at Sartorius

Quentin Huault holds a PhD in organic chemistry from the University of Strasbourg. He supplemented his synthetic chemistry knowledge with two post-doctoral fellowships at Merck (UK) and at CEA (France), developing both polymeric materials and small molecules for various

applications. After 2 years focusing on innovative polymers-based transfection reagents at Sartorius-Polyplus, he has been in charge since 2023 of the chemical development of the non-viral delivery solutions addressing both in vivo and ex vivo applications.



Rein Verbeke
Senior postdoc at Ghent University (NanoMedicine Centre)

Dr. Rein Verbeke is a senior postdoc in the Ghent Research Group on Nanomedicines (Ghent University, <https://www.drugdelivery.be>). His PhD focused on the design of mRNA-LNPs and the adjuvancy of mRNA vaccines. Rein continued his research on the validation of a glycolipid-adjuvanted mRNA vaccine (Galsomes) for cancer and intracellular bacterial infections. In 2022, he visited the

group of Prof. Pieter Cullis, University of British Columbia, where he investigated the contribution of LNPs to the immunogenicity and reactogenicity of mRNA vaccines. Rein is also director of the Ghent Nanomedicine Center providing solutions for the formulation and in-depth characterization of bio-therapeutics in nanoparticles.



Maciej Drozd
Co-founder and CBO at MiMo Biotech

Dr. Maciej Drozd, MBA has over 15 years of experience spanning biotechnology investment, company creation, and technology commercialization. Throughout his career, he has held roles as an investor, board member, and operating executive across a range of life science companies. Trained as a scientist, he earned a Ph.D. in Biology from the University of Heidelberg and an MBA from Saïd Business School at the University of Oxford. Maciej has held senior positions at Johnson & Johnson

Development Corporation, Entrepreneurs Fund, and Atlas Venture, where he led investments, served on multiple boards, and supported companies from early formation through clinical development, IPO, and successful exits. His expertise includes mergers and acquisitions, private and public equity investing, portfolio management, and full profit-and-loss responsibility across biotech, medtech, and digital health.



Mark Dickman

Professor of Bioanalytical Science and Engineering at University of Sheffield

Mark Dickman is Professor of Bioanalytical Science and Engineering at the University of Sheffield. He obtained his degree and PhD at the Krebs Institute, University of Sheffield. Following his PhD he joined a biotechnology company, Transgenomic where he worked as a research scientist developing analytical techniques including DNA/RNA Chromatography. He joined the Dept of Chemical and Biological Engineering in 2003. His research focuses on

the development and application analytical techniques to study biological molecules. In particular, bioseparations in conjunction with biological mass spectrometry are used to characterise and analyse nucleic acid therapeutics. They have established a dedicated RNA bioanalytical facility for the characterisation of mRNA CQAs. He is a Director and co-founder of a University spin out company RNA Forge.



Deborah Entiriwaa

DNA Operations Team Leader at 4basebio

Deborah Entiriwaa is a Biomedical scientist and Molecular Biologist with 6 years of experience in industry and is currently the MSAT RUO Product Team Lead at 4basebio, an innovative platform technology company focussed on the production of synthetic DNA products for gene therapy and vaccine development. Deborah is responsible for overseeing and strategizing the production of unique and catalogue products for RUO client projects for a

multitude of applications including mRNA, AAV and Gene editing. Previously Deborah has had experience in immunoassay design and development at Wageningen Food Safety & Research in The Netherlands, investigating milk fraud and adulteration on an EU Horizon 2020 project as well as working at a COVID response centre providing nationwide COVID testing, this is where she earned her HCPC Biomedical Scientist registration.



Michel Bajiot

Board Director at RNAlead and Chairman at White Fund

Mr. Bajiot holds a PhD in molecular biology from the University of Louvain in Belgium. He is a biochemist engineer and brings more than 25 years of experience from senior roles in the global biotechnology and vaccine industry of both developed and developing countries. His previous positions include Worldwide Vice President Strategy, Licensing & M&A at GSK Vaccines, Chief

Business Officer at Janssen Crucell Vaccines, Executive Director Europe at Serum Institute of India, Board Director at Sinovac, Chairman at Radiomics, Corporate Director Molecular Diagnostics at bioMérieux. Mr. Bajiot serves as Chairman at White Fund and at CuraVac, as Board Director at RNAlead and at Expres2ion Biotech, and as Advisor at Noshag.




Andreas Kuhn

Senior Vice President RNA Biochemistry & CMC Development at BioNTech

Andreas Kuhn has worked with RNA for almost thirty years. This started with his diploma and PhD theses on the structure and function of small non-coding RNAs using biochemical and molecular biology methods. In his post-doctoral work, Andreas studied RNA-protein interactions in the spliceosome in yeast and later worked on small molecules to affect pre-mRNA splicing. His work on mRNA-based immunotherapies began in 2007 in the academic group of Ugur Sahin at the University Clinic Mainz, and Andreas joined BioNTech SE shortly

after its founding in 2008. In his current role as Senior Vice President RNA Biochemistry & CMC Development the main focus is expanding proprietary technologies to increase the efficacy of mRNA-based therapies and to develop and optimize GMP-compatible manufacturing processes and analytical methods for RNA. He has co-authored numerous publications and patents ranging from basic research on RNA to its application as a therapeutic agent and vaccine.



Marco Pupo

Innovation and Development Coordinator at ANEMOCYTE Srl

Marco holds a background in Pharmaceutical Technology and Biochemistry, bringing over a decade of academic and industry experience in biotechnology R&D. He has successfully coordinated cross-functional teams in matrixed environments, overseeing international programs from proof-of-concept to GMP technology transfer. Marco specializes in process and analytical

development for non-viral cell therapies, proteins, and nucleic acid-based therapeutics. An expert inventor in the RNA field, he has pioneered breakthrough single-pot and simultaneous co-transcriptional in vitro capping technologies (AMCAP™) to streamline scale-up and reduce manufacturing bottlenecks for therapeutic mRNA.



Blerina Shkodra

Chief Scientific Officer at leon-nanodrugs GmbH

Blerina is Chief Scientific Officer at LEON-nanodrugs GmbH in Munich, where she drives scientific and technology strategy for the company's nanoparticle manufacturing platform. A drug-product development leader specializing in LNPs and other parenteral nanoparticle systems, she has expertise in formulation, process development, and technology transfer, with recent work focused on the robustness and scalability of mRNA-LNP manufacturing.

Since joining LEON in 2022, she has focused on building the company's particle science and formulation capabilities, and previously worked on RNA-based drug-product process development at CureVac. She holds a PhD in Nanomedicine and Drug Delivery from Friedrich Schiller University Jena and two master's degrees from the University of Greenwich and Charles University.




Harvey Branton

Senior Translation Consultant at eXmoor Pharma

Harvey is a Senior Translation Consultant at eXmoor Pharma, where he supports a broad range of client projects and leads the development of in-house mRNA and LNP manufacturing capability within eXmoor's new licensed facility. With more than 30 years of experience in bioprocessing, Harvey brings deep expertise spanning R&D, automation, manufacturing support, and production management, with a particular focus on bridging the gap between research and GMP manufacturing. He has

directed multiple RNA and LNP development programmes, including the transfer and scale-up of Imperial College's self-amplifying mRNA COVID-19 vaccine. Harvey also played a key role in establishing CPI's RNA Centre of Excellence, which included the creation of a GMP manufacturing facility for RNA and LNP as well as a dedicated training academy to accelerate workforce skills and sector-wide understanding of RNA manufacturing.



Charles Chesnelong

Field Application Scientist at Cytiva

Charles Chesnelong is a Field Application Scientist within Cytiva's Nanomedicine team, supporting the pharmaceutical development of lipid nanoparticle (LNP) therapeutics. His scientific interests focus on the

development and application of LNPs across a range of therapeutic modalities, including in vivo CAR-T, gene replacement, gene editing, gene silencing, and vaccines for infectious diseases and cancer immunotherapy.




Andrea Cusack

CEO at Nebu~flow

Andrea Cusack is a senior international life sciences executive with 25+ years' experience across pharma, biotech and CDMOs (GSK, Catalent, West Pharma, leon nanodrugs). She is CEO of Nebuflow and a strategic board advisor to Instapill. Andrea brings end-to-end expertise across Chemistry, Manufacturing and Controls (CMC),

from early development through commercialisation, spanning a wide range of dosage forms and delivery technologies for both small and large molecules. She provides effective oversight of development, manufacturing strategy and operational risk in complex growth-stage environments.



Sabine Maamari

Chief Operating Officer at Avocet Bio

Dr Sabine Maamari is the Chief Operating Officer of Avocet Bio, a German biotechnology company developing programmable RNA medicines. She leads the company's operational strategy, partnerships, non-clinical development, and funding activities. Her work focuses on

translating innovative RNA technologies into therapeutic programmes, particularly in cardiovascular disease and fibrosis. She holds a PhD in Molecular Medicine, with a focus on cardiovascular epigenetics.







Lil' Tuna

Plate-based buffer exchange & concentration


- Plate-based or single sample exchanges
- 100 μ L to 8 mL
- $\geq 96\%$ recovery
- Automation compatible



Sunshine

Create the perfect therapeutic nanoparticle


- Automated nanoparticle development
- Fully reusable microfluidics
- Options from 400 μ L to continuous flow
- Automated cleaning



Sunscreen

Automated nanoparticle formulation screening

- Walk-away automated screening
- 3-4 minutes per experiment
- 400 μ L per experiment (3:1 ratio)
- Fully reusable microfluidics



Sunbather



GMP nanoparticle production

- Up to 1.8 L/h
- Integrated in-line dilution
- Fully replaceable flow path
- 21 CFR Part 11 compliant software

HOTEL EUROSTARS UNIVERSAL

Located in Lisbon's modern Parque das Nações district, the Eurostars Universal Lisboa is a contemporary five-star hotel offering an elegant setting for international conferences and executive networking. Positioned in one of the city's leading business and innovation hubs, the hotel combines modern design, premium comfort, and excellent accessibility.

The venue features sophisticated meeting facilities, stylish accommodation, and high-quality amenities, including a rooftop swimming pool, fitness centre, wellness facilities, and several dining options. Just minutes from Lisbon International Airport and close to the city's waterfront, restaurants, and attractions, the Eurostars Universal Lisboa provides an ideal environment for the FormuTech Summit 2026.



AVENIDA DO D. JOÃO II
PARQUE DAS NAÇÕES, 1990-050
LISBOA



 EUROSTARS

 EUROSTARS UNIVERSAL LISBOA

